FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:519-520 January 29, 2004 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Terkeltaub, R. A. PubMed Citation

To the Editor: In discussing treatment options for gout (Oct. 23 issue),¹ Terkeltaub omitted the emerging role of fenofibrate. This fibric-acid derivative is used to treat various forms of hyperlipidemia and has recently been shown to prevent the progression of coronary artery disease.² Fenofibrate is unique among the fibrates because of its uricosuric properties and has been shown to lower serum urate levels by 19 percent in men with gout receiving established therapy with allopurinol.³ Remission of clinical episodes of gout over several years has also been reported.⁴

Furthermore, although this notion is controversial, high urate levels may be an . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.